PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing
LYON, France --(BUSINESS WIRE)--Nov. 6, 2017-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP) (ADR: EYRYY) (“ERYTECH” or the "Company") (Paris:ERYP) (ADR:EYRYY) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing
LYON, France --(BUSINESS WIRE)--Nov. 6, 2017-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP) (ADR: EYRYY) (“ERYTECH” or the "Company") (Paris:ERYP) (ADR:EYRYY) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
LYON, France --(BUSINESS WIRE)--Oct. 10, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has resubmitted to the
View HTML
Toggle Summary ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
LYON, France --(BUSINESS WIRE)--Oct. 10, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has resubmitted to the
View HTML
Toggle Summary ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States
LYON, France --(BUSINESS WIRE)--Oct. 6, 2017-- ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP) (“ERYTECH”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has
View HTML
Toggle Summary ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States
LYON, France --(BUSINESS WIRE)--Oct. 6, 2017-- ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP) (“ERYTECH”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has
View HTML
Toggle Summary Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –September 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Oct. 6, 2017-- Regulatory News : Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut (1) voting rights   Total of net (2) voting rights
View HTML
Toggle Summary Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –September 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Oct. 6, 2017-- Regulatory News : Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut (1) voting rights   Total of net (2) voting rights
View HTML
Toggle Summary ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL
Dose of 100 U/kg, which is the same dose used in other studies with eryaspase in adult acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and metastatic pancreatic cancer patients, was recommended for further evaluation of eryaspase in pivotal study in first line adult ALL LYON,
View HTML
Toggle Summary ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL
Dose of 100 U/kg, which is the same dose used in other studies with eryaspase in adult acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and metastatic pancreatic cancer patients, was recommended for further evaluation of eryaspase in pivotal study in first line adult ALL LYON,
View HTML
Top